Joshua McGee
Chief Scientific Officer & Co-Founder Keylicon Biosciences
Seminars
Thursday 1st October 2026
Durable RNA Vaccines & Therapies: Unlocking the Manufacturing & CMC Potential of Next-Generation Self- Amplifying RNA Platforms
1:40 pm
- Exploring how self-amplifying RNA (saRNA) platforms can reshape manufacturing economics through lower dose requirements, increased protein expression, and enhanced durability compared with conventional mRNA approaches
- Addressing the unique CMC and scale-up considerations associated with saRNA development, including construct complexity, analytical characterisation, stability optimization, and process consistency at larger scales
- Designing platform-ready manufacturing strategies that enable flexible translation across vaccines and therapeutics while maintaining speed, quality, and commercial scalability
- Evaluating how next-generation RNA modalities may influence future supply chain demands, CDMO partnerships, and regulatory expectations as the industry moves beyond first-generation mRNA systems
